These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26380149)

  • 1. Novel antidotes for target specific oral anticoagulants.
    Das A; Liu D
    Exp Hematol Oncol; 2015; 4():25. PubMed ID: 26380149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific antidotes in development for reversal of novel anticoagulants: a review.
    Gomez-Outes A; Suarez-Gea ML; Lecumberri R; Terleira-Fernandez AI; Vargas-Castrillon E
    Recent Pat Cardiovasc Drug Discov; 2014; 9(1):2-10. PubMed ID: 25494843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal Agents for Direct Oral Anticoagulants: Understanding New and Upcoming Options.
    Rogers KC; Shelton MP; Finks SW
    Cardiol Rev; 2016; 24(6):310-315. PubMed ID: 27548686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
    Boda Z
    Orv Hetil; 2016 Mar; 157(12):443-50. PubMed ID: 26971644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring and reversal strategies for new oral anticoagulants.
    Vanden Daelen S; Peetermans M; Vanassche T; Verhamme P; Vandermeulen E
    Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):95-103. PubMed ID: 25431993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.
    Enriquez A; Lip GY; Baranchuk A
    Europace; 2016 Jul; 18(7):955-64. PubMed ID: 25816811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Andexxa--an antidote for apixaban and rivaroxaban.
    Med Lett Drugs Ther; 2018 Jun; 60(1549):99-101. PubMed ID: 29913471
    [No Abstract]   [Full Text] [Related]  

  • 9. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the development of specific antidotes for target-specific oral anticoagulants.
    Mo Y; Yam FK
    Pharmacotherapy; 2015 Feb; 35(2):198-207. PubMed ID: 25644580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic Reversal of Direct Oral Anticoagulants.
    Farina N; Miller JT
    Crit Care Nurs Q; 2018; 41(2):121-128. PubMed ID: 29494368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of agents for reversing the effects of target-specific oral anticoagulants.
    Riley TR; Gauthier-Lewis ML; Sanchez CK; Douglas JS
    Am J Health Syst Pharm; 2017 Jan; 74(2):54-61. PubMed ID: 27895055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.
    Kaatz S; Mahan CE; Nakhle A; Gunasekaran K; Ali M; Lavender R; Paje DG
    Curr Cardiol Rep; 2017 Oct; 19(12):124. PubMed ID: 29064044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.
    Kustos SA; Fasinu PS
    Medicines (Basel); 2019 Oct; 6(4):. PubMed ID: 31618893
    [No Abstract]   [Full Text] [Related]  

  • 16. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants.
    Ansell JE
    J Thromb Thrombolysis; 2016 Feb; 41(2):248-52. PubMed ID: 26449414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
    Giustozzi M; Verso M; Agnelli G; Becattini C
    J Thromb Thrombolysis; 2017 Nov; 44(4):527-535. PubMed ID: 28913672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
    PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal strategies in patients treated with direct oral anticoagulants.
    Gressenberger P
    Vasa; 2019 Aug; 48(5):389-392. PubMed ID: 30719950
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antidotes to novel direct oral anticoagulants].
    Khorev NG; Momot AP; Kon'kova VO
    Angiol Sosud Khir; 2016; 22(3):177-83. PubMed ID: 27626268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.